Please Wait...

TGF-β1 // Transforming Growth Factor beta 1

Biomarker Therapeutic Areas: 
Biomarker Matrices: 

Transforming Growth Factor β1 (TGF-β1), an homodimer of two 12.5 kDa subunits, belongs to the TGF β superfamily which comprises Bone Morphogenetic Proteins, activins, inhibins, growth differentiation factors and myostatin. There are three isoforms of TGF β (TGF-β1, TGF-β2 and TGF-β3) encoded by three different genes. Even if these three isoforms interact with the same receptor (heterodimer of TGFR-1 and TGFR-2), they are implicated in slightly different biological functions (Lafyatis, 2014). TGF-β1 is secreted together with its latency associated pro-peptide (LAP), is active only after a complete posttranslational process and releasing from LAP association (which can be, for example, provoked by mechanical stimulation) (Hinz, 2015). TGF-β family is implicated in numerous biological process such as regulation of cell proliferation, migration and adhesion of differentiated cells, extracellular matrix production, induction of stromal cytokine, fibrosis and in modifying tumor micro-environment (Massagué, 2012).

Bioclinica Lab employs a manual sandwich immunoassay specific for TGF-β1 measurement in serum.

ADDITIONAL RESOURCES

Biomarker Menu

Download MENU

Molecular Marker Laboratory Services

Download Brochure

Alzheimer's Disease Biomarker Lab Expertise

Download Info Sheet

Leader in Clinical Trial
Management Solutions

Successful clinical trials require the ability to see key details and uncover hidden insights. Bioclinica utilizes science and technology to bring clarity to clinical trials, helping companies to develop new life-improving therapies more efficiently and safely.

Still time to catch up on summer reading on recent developments in #Alzheimer's Disease Fluid Biomarkers here int t… https://t.co/kyQmz7FxlN
bioclinica (Yesterday)
Our clients have substantial success w #eSource, some spanning well over a decade. Still other organizations remain… https://t.co/UwVs6ajPp4
bioclinica (2 days ago)
Our clients have substantial success w #eSource, some spanning well over a decade. Still some in the industry remai… https://t.co/ASuUvN6xb9
bioclinica (4 days ago)
RT @RfwrightLSL: When Do You Think #BYOD (Bring Your Own Device) Will Become Widely Used To Capture PRO Data In #Clinical #Research? https:…
bioclinica (1 week ago)
ICYMI: Our V.P./Head of Neuroscience & Cardiovascular Svcs., Dr. Joyce Suhy, talks about challenges in determining… https://t.co/Lns6B3VPPN
bioclinica (1 week ago)
RT @FCR_News_Today: FDA Issues New Guides on Use of Electronic Health Information in #ClinicalTrials. #ClinicalResearch https://t.co/j8LHV2…
bioclinica (2 weeks ago)

Latest Blogs:

Latin America: Benefit from the Right Partner
Removing Risk from Clinical Trial Management System (CTMS) Implementations
Collaboration Between Clinical Operations and the Logistics and Supply Chain Teams is Key to Trial Success
The Value of Protocol Review
CTMS and RBM: Hot Topics at OCT Nordics in Copenhagen